Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel imidazoline antimicrobial scaffold that inhibits DNA replication with activity against mycobacteria and drug resistant Gram-positive cocci.

ACS chemical biology - 21 Nov 2014

Harris Kendra K, Fay Allison, Yan Han-Guang, Kunwar Pratima, Socci Nicholas D, Pottabathini Narender, Juventhala Ramakrishna R, Djaballah Hakim, Glickman Michael S

Abstract excerpt

Bacterial antimicrobial resistance is an escalating public health threat, yet the current antimicrobial pipeline remains alarmingly depleted, making the development of new antimicrobials an urgent need. Here, we identify a novel, potent, imidazoline antimicrobial compound, SKI-356313, with bactericidal activity against Mycobacterium tuberculosis and Gram-positive cocci, including vancomycin-resistant Enterococcus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to DNA Replication

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Mycobacterium

Share to Structure-Activity Relationship

Source

Open in PubMed Open full text

Identifiers

PMID: 25222597
DOI: 10.1021/cb500573z
PMCID: PMC4245167

Genes

SKI

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel imidazoline antimicrobial scaffold that inhibits DNA replication with activity against mycobacteria and drug resistant Gram-positive cocci.PMID 25222597Read ↗

The phenotypic landscape of the mycobacterial cellSemantic proximity Read ↗

A chemical-genetic map of the pathways controlling drug potency in <i>Mycobacterium tuberculosis</i>Semantic proximity Read ↗

Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessusSemantic proximity Read ↗

CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosisSemantic proximity Read ↗

Saskemycin, a potent and selective antimycobacterial agent targeting a unique site on the ribosomeSemantic proximity Read ↗

Pyrimidine Analogues as a New Class of Gram-Positive Antibiotics, Mainly Targeting Thymineless-Death Related ProteinsSemantic proximity Read ↗

Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanismSemantic proximity Read ↗

A small molecule that inhibits the evolution of antibiotic resistanceSemantic proximity Read ↗

Illuminating host-mycobacterial interactions with functional genomic screening to inhibit mycobacterial pathogenesisSemantic proximity Read ↗

Conditional silencing of topoisomerase I gene of Mycobacterium tuberculosis validates its essentiality for cell survival.Semantic proximity Read ↗

Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous MycobacteriaSemantic proximity Read ↗

Antibiotic lethality dictates mycobacterial infection outcomesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.